Search results for "Endogenous depression"

showing 10 items of 12 documents

Results of an Open Clinical Trial of Brofaromine (CGP 11 305 A), a Competitive, Selective, and Short-Acting Inhibitor of MAO-A in Major Endogenous De…

1987

In an open clinical trial the authors treated 18 hospitalized patients suffering from endogenous depression with brofaromine (CGP 11305A), a competitive, selective, and short-acting inhibitor of type A monoamine oxidase (MAO). Four patients were defined as good responders, as they had a final HAMD score of between 0 and 7 points. Four patients were judged as improved, with final HAMD scores of between 8 and 15 points, while the remaining eight patients failed to respond (final HAMD score greater than or equal to 16 points). The major observations were a beneficial influence on drive in most patients, while paranoid symptoms worsened markedly, rendering the substance contraindicated in psych…

AdultBlood PlateletsMaleSerotoninMonoamine Oxidase Inhibitorsmedicine.medical_treatmentSleep REMTyraminePsychotic depressionPharmacologyPersonality AssessmentDexamethasonechemistry.chemical_compoundPiperidinesBrofaromineHamdmedicineHumansPharmacology (medical)Monoamine OxidaseDepression (differential diagnoses)AgedDepressive DisorderChemotherapybiologyElectroencephalographyGeneral MedicineMiddle Agedmedicine.diseaseClinical trialPsychiatry and Mental healthchemistryEndogenous depressionbiology.proteinFemaleMonoamine oxidase APsychologyPharmacopsychiatry
researchProduct

Reliability and validity of the Newcastle Scales in relation to ICD-9-classification

1987

The assessment of endogenous depression by means of the Newcastle Scales (1965, 1971) has been validated by their correlation with biological findings in many previous studies. However, reliability and cross validation studies are lacking for these scales. We found the reliability of the Newcastle Scales to be sufficient or at least moderate in a sample of 70 inpatients with major depression. In order to cross validate both scales, the clinical classification according to ICD-9 and the assessment of the Newcastle Scales have been performed independently in a sample of 112 inpatients with Major Depressive Disorder (RDC). The rate of agreement between clinical diagnosis and classification acc…

AdultMalePsychiatric Status Rating ScalesDepressive Disordermedicine.medical_specialtyPsychometricsPsychometricsTest validityMiddle Agedmedicine.diseaseCross-validationCorrelationPsychiatry and Mental healthRating scaleEndogenous depressionmedicineHumansMajor depressive disorderFemalePsychiatryPsychologyReliability (statistics)Clinical psychologyActa Psychiatrica Scandinavica
researchProduct

A polydiagnostic scale for dimensional classification of endogenous depression. Derivation and validation.

1986

Several operational diagnoses (OPD) for endogenous depression have been proposed. However--though aiming at similar clinical concepts--the amount of association and agreement between different OPD is rather low. In this study the relationship between eight OPD (Research Diagnostic Criteria, DSM-III, Michigan Discrimination Index, Newcastle Scale I, Newcastle Scale II, Taylor-Abrams Criteria, Vienna Research Criteria, Hamilton Endogenomorphy Index) was assessed by applying latent trait analyses to the classificatory data of these eight OPD which were rated simultaneously in a sample of 173 depressive inpatients. According to these analyses six OPD (RDC, DSM-III, NCS-I, NCS-II, TAC and VRC) a…

AdultMalePsychiatric Status Rating Scalesmedicine.medical_specialtyDepressive DisorderBipolar DisorderPsychometricsScale (ratio)Neurotic DisordersPsychometricsResearch Diagnostic CriteriaTest validityPsychiatry and Mental healthAdjustment DisordersManuals as TopicLatent traitEndogenous depressionmedicineSchizophreniaHumansFemaleMedical diagnosisPsychiatryPsychologyDepression (differential diagnoses)Acta psychiatrica Scandinavica
researchProduct

Differential effects of the enantiomers R(-) and S(+) oxaprotiline on major endogenous depression, the sleep EEG and neuroendocrine secretion: studie…

1993

The effects of the optically active enantiomers of oxaprotiline (OXP), R(-) OXP and S(+) OXP, on depressive symptomatology and the sleep EEG were investigated in two separate exploratory studies. In addition, the neuroendocrine profile of both compounds was characterized in normal controls. In the patients treated with a daily oral dose of 150 mg S(+) OXP we found a Hamilton depression score that decreased from 29.1 +/- 1.8 (SEM) on day 0 to 14.7 +/- 3.2 on day 28 (P0.01). Six patients were judged to be full responders (HAMD score 0-7 points), three were improved (HAMD score 8-15) and four were nonresponders (HAMD score16). The therapeutic effect achieved with 150 mg R(-) OXP daily was less…

AdultMalemedicine.medical_specialtyHydrocortisoneSleep REMchemistry.chemical_compoundNorepinephrineInternal medicineHamdmedicineHumansPharmacology (medical)SecretionTestosteroneBiological PsychiatryTestosteroneAgedPharmacologyPsychiatric Status Rating ScalesDepressive DisorderNeurosecretionPenile ErectionTherapeutic effectOxaprotilineElectroencephalographyStereoisomerismMiddle AgedProlactinAntidepressive AgentsProlactinPsychiatry and Mental healthEndocrinologyNeurologychemistryMaprotilineGrowth HormoneEndogenous depressionFemaleNeurology (clinical)EnantiomerPsychologySleepEuropean neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology
researchProduct

Multisteroid analysis after DST in depressed patients — A controlled study

1986

Abstract 111 consecutively admitted in-patients with a depressive syndrome received a dexamethasone suppresion test (DST) after all known factors which might confound the test results had been carefully excluded. Plasma concentrations of cortisol, corticosterone and dexamethasone were compared with several diagnostic evaluations (RDC, DSM-III, ICD-9) in a controlled study. The positive predictive value of nonsuppressed corticosteroid levels was only moderate for each diagnostic category. Diagnostic specificities were 84.6% for major depression, endogenous subtype (RDC), 71.2% for melancholia (DSM-III) and 86.8% for endogenous depression (IDC-9) when using a post-DST cortisol value above 50 …

AdultMalemedicine.medical_specialtyHydrocortisonemedicine.drug_classDexamethasonechemistry.chemical_compoundCorticosteroneInternal medicineMelancholiamedicineHumansDepression (differential diagnoses)DexamethasoneAgedDepressive DisorderMiddle AgedAntidepressive AgentsPsychiatry and Mental healthClinical PsychologyEndocrinologychemistryDexamethasone suppression testEndogenous depressionCorticosteroidFemaleMajor Diagnostic Categorymedicine.symptomCorticosteronePsychologymedicine.drugJournal of Affective Disorders
researchProduct

Effect of sulpiride in endogenous depression.

1984

Clinical practice and pharmacological data suggest a possible antidepressive action of sulpiride given in low dosages. To further explore the therapeutic efficacy of sulpiride 11 patients with an endogenous type of depression were studied during treatment with an oral daily dose of 150 mg sulpiride. The present data allows the conclusion that (A) low dosed sulpiride seems to act as an antidepressant in severe and milder forms of depression, (B) a clinical progress is seen earlier than is common during treatment with tricyclics and (C) a significant increase of drive is observable. However, sulpiride maintenance therapy did not prevent early relapse into depression. The preliminary nature of…

DrugAdultMalemedicine.medical_specialtyTime FactorsDosemedia_common.quotation_subjectEarly RelapsePharmacologyMaintenance therapymedicineHumansPsychiatryDepression (differential diagnoses)media_commonClinical Trials as TopicDepressive DisorderMiddle AgedPsychiatry and Mental healthEndogenous depressionAntidepressantFemaleSulpiridePsychologySulpiridemedicine.drugActa psychiatrica Scandinavica. Supplementum
researchProduct

The Hamilton Depression Scale and Its Alternatives: A Comparison of Their Reliability and Validity

1990

The efficacy of medical treatments is evidenced by a demonstrated reduction in the severity of the disorder being treated relative to a control condition. At the beginning of the era of psychopharmacology, in the late 1950s, neither a well-defined concept nor a well-defined measurement of the severity of depression, schizophrenia, or anxiety disorders were available. Consequently, it was difficult to compare groups of treated patients on the basis of treatment-specific rates of recovery. Hamilton was one of the first to recognize this lack and to create methods for standardizing the measurement of the effects of drugs across both patients and treatments. His idea was that a standardized mea…

Hamilton depression scalebusiness.industryMEDLINEmedicine.diseaseSchizophreniaEndogenous depressionmedicineAnxietyPsychopharmacologymedicine.symptombusinessDepression (differential diagnoses)Reliability (statistics)Clinical psychology
researchProduct

The dexamethasone suppression test in depressed patients: Clinical and biochemical aspects

1983

Summary Endogenous depression (ED) is regarded as a psychiatric disease with a biological pathogenesis. Consequently patients with ED respond favourably to somatic treatment, whereas for non-endogenously depressed patients drug-treatment would be often inappropriate. Until now, psychopathologists have failed to define precisely the endogenous subtype of depression on clinical features alone. It is well established that a subgroup of depressed patients shows hypersecretion of Cortisol and consequently inadequate suppression of Cortisol after a test dose of dexamethasone. This dexamethasone suppression test (DST) was introduced as a laboratory marker, specifically identifying endogenously dep…

OncologyNosologymedicine.medical_specialtyeducation.field_of_studybusiness.industryPopulationPsychoactive drugBiochemistrySomatic psychologyEndocrinologyEndocrinologyInternal medicineDexamethasone suppression testEndogenous depressionmedicinebusinesseducationDepression (differential diagnoses)Dexamethasonemedicine.drugJournal of Steroid Biochemistry
researchProduct

The impact of the endogenous subtype on the familial aggregation of unipolar depression.

1991

The endogenous/non-endogenous distinction of unipolar major depression is widely accepted, as is the family study approach to the validation of diagnostic distinctions. Rates of affective disorders were examined in 689 first-degree relatives of 184 patients with unipolar major depression and were compared with 312 first-degree relatives of 80 healthy controls. Only unipolar depression and alcoholism were more common in families of depressed probands compared with families of healthy controls. As a variety of diagnostic definitions of endogenous depression have been proposed, probands and relatives were diagnosed in a polydiagnostic manner. None of the five diagnostic definitions of endogeno…

ProbandMalemedicine.medical_specialtyEndogenybehavioral disciplines and activitiesDelusionsArousalDiagnosis DifferentialChild of Impaired ParentsRisk Factorsmental disordersmedicineHumansPharmacology (medical)PsychiatryBiological PsychiatryDepression (differential diagnoses)Depressive DisorderGeneral NeuroscienceMental DisordersFamily aggregationGeneral MedicineFamilial riskMiddle AgedCircadian RhythmPsychiatry and Mental healthNeuropsychology and Physiological PsychologyPhenotypeEndogenous depressionFemalePsychologyArousalClinical psychologyEuropean archives of psychiatry and clinical neuroscience
researchProduct

Functional Classification and Response to Psychotropic Drugs

1990

Psychopathologically defined diagnoses represent guidelines for the application of drugs and serve as selection criteria for the evaluation of potentially useful psychopharmacological agents. Therefore, the success of research in drug evaluation strongly depends on the conceptual frameworks of diagnostic classification and how these change. For instance, at the beginning of the era of antidepressants 30 years ago, the efficacy of antidepressants was thought to be restricted to patients with endogenous depression, but since then their therapeutic spectrum has broadened: first to the “depressive syndrome” and then, due to the growing acceptance of DSM-III, to the major depressive episode. Now…

Research designDrugmedicine.medical_specialtyGeneralized anxiety disorderbusiness.industryPanic disordermedia_common.quotation_subjectmedicine.diseasePsychotropic drugEndogenous depressionMedicinemedicine.symptombusinessMajor depressive episodePsychiatryAnxiety disordermedia_common
researchProduct